Want to join the conversation?
$ALXN's research and development expenses for 2015 rose by 38% from 2014. The increase was primarily related to rise in clinical expenses on expansion of studies for eculizumab, ALXN 1007, ALXN 1210, and other programs, licensing agreement expenses, discovery research, payroll and benefit expenses as well as facilities and other costs.
Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.
Waiting with fingers crossed for $AAPL’s fourth quarter earnings.
Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."